

## Myocardial Ischemia Market Size, Share, Revenue, Trends And Drivers For 2024-2033

The Business Research Company's Myocardial Ischemia Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033

LONDON, GREATER LONDON, UK, August 20, 2024 /EINPresswire.com/ --The global myocardial ischemia market has experienced significant growth in

The Business **Research** Company

Myocardial Ischemia Global Market Report 2024 -Market Size, Trends, And Global Forecast 2024-2033

recent years. It is projected to increase from \$0.74 billion in 2023 to \$0.79 billion in 2024, achieving a compound annual growth rate (CAGR) of 6.7%. Despite challenges from various factors, the market is anticipated to reach \$1.04 billion by 2028 at a compound annual growth rate (CAGR) of 7.0%, driven by rising prevalence of heart-related diseases and advancements in

"

You Can Now Pre Order Your Report To Get A Swift Deliver With All Your Needs

> The Business Research Company

treatment options.

Rising Incidence of Diabetes Drives Market Growth One of the primary factors fueling the growth of the myocardial ischemia market is the increasing incidence of diabetes. Diabetes, characterized by the body's inability to produce or effectively use insulin, significantly raises the risk of myocardial ischemia. The prevalence of diabetes is escalating due to factors such as obesity, lack of physical

activity, and genetic predispositions. According to the International Diabetes Federation (IDF), the number of adults aged 20–79 living with diabetes globally was approximately 537 million in 2021. This figure is expected to rise to 643 million by 2030 and 783 million by 2045. The growing prevalence of diabetes is anticipated to boost demand for myocardial ischemia diagnostic and therapeutic solutions.

Explore comprehensive insights into the global myocardial ischemia market with a detailed sample report:

https://www.thebusinessresearchcompany.com/sample\_request?id=16488&type=smp

Major players in the myocardial ischemia market include Cardinal Health Inc., Pfizer Inc., Roche Holding AG, Bayer AG, and Sanofi SA, among others. These companies are at the forefront of developing innovative treatments to manage myocardial ischemia. For example, Agepha Pharma launched Lodoco (colchicine) in June 2023, an FDA-approved treatment targeting cardiovascular inflammation. This drug aims to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death. Lodoco's approval highlights the industry's commitment to advancing treatment options for myocardial ischemia.

Trends Shaping the Market

Several trends are influencing the myocardial ischemia market:

- Adoption of Treatments: Increased adoption of myocardial ischemia treatments and advancements in healthcare infrastructure.
- Digital Health Solutions: Integration of digital health solutions and launches of cardiac rehabilitation programs.

• Innovations in Treatment: Continuous advancements in treatment options, driven by both pharmaceutical innovations and technological enhancements.

## Market Segmentation

The myocardial ischemia market is segmented as follows:

- By Type: Symptomatic, Asymptomatic
- By Treatment and Diagnosis: Diagnosis, Treatment
- By End-User: Hospitals and Clinics, Diagnostic Centers, Ambulatory Surgery Centers

Regional Insights: North America Leading the Market

North America led the myocardial ischemia market in 2023, thanks to advanced healthcare infrastructure and high awareness levels. However, Europe is expected to be the fastest-growing region in the forecast period, driven by increasing healthcare expenditure and growing patient awareness.

Explore the report store to make a direct purchase of the report

https://www.thebusinessresearchcompany.com/report/myocardial-ischemia-global-marketreport

Myocardial Ischemia Global Market Report 2024 from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

• Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Myocardial Ischemia Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on <u>myocardial ischemia market size</u>,

myocardial ischemia market drivers and trends, myocardial ischemia market major players, competitors' revenues, market positioning, and market growth across geographies. The myocardial ischemia market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company: Myocardial Infarction Global Market Report 2024 <u>https://www.thebusinessresearchcompany.com/report/myocardial-infarction-global-market-report</u>

Critical Limb Ischemia Global Market Report 2024 <u>https://www.thebusinessresearchcompany.com/report/critical-limb-ischemia-global-market-report</u>

Cardiac Pacemakers Global Market Report 2024 <u>https://www.thebusinessresearchcompany.com/report/cardiac-pacemakers-global-market-</u> <u>report</u>

About The Business Research Company?

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information The Business Research Company Europe: +44 207 1930 708 Asia: +91 8897263534 Americas: +1 315 623 0293

Oliver Guirdham The Business Research Company + +44 20 7193 0708 email us here Visit us on social media: Facebook X

## LinkedIn YouTube

This press release can be viewed online at: https://www.einpresswire.com/article/736031070

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.